Skip to content

Pain

The Global Pain Market 2008-2023

 

Publication Date November 2008
Publisher Visiongain
Product Type Report
Pages 102
ISBN Number not applicable
Product Code VIS00089

Price

£1,499.00
approximately: $2,270 | €1,673

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

The global pain market generated total sales of $34bn in 2007 - but what will the figures be in the next 5 and 10 years? This report tells you.

The pain market has marked strengths and advantages, but is also limited by problems and concerns. The market will be driven by new drugs and reformulations of existing ones - but which drugs will be most successful? The incidence of pain is increasing rapidly, what some experts call a pain epidemic - so the opportunities available to an additional blockbuster drug is significant. The prevention and treatment of pain is already one of the highest priorities for healthcare authorities in the world, yet for mature markets pain drug sales have fallen. However, visiongain believes that this market has strong growth potential, despite the prospect of generic competition for leading branded products.

The pain market contained four blockbuster drugs in 2007. Visiongain predicts that there will be room for more blockbuster drugs in that market segment during the years ahead as new products are launched, replacing older products. There is great potential for treatments with greater safety, efficacy and tolerability. This report - The Global Pain Market, 2008-2023 - provides analysis and forecasts for the overall pain market and its principal subdivisions, as well as for leading products within those categories. This study also highlights promising pipeline developments and important contemporary issues, especially commercial drivers and restraints.

In particular, The Global Pain Market, 2008-2023 analyses global markets for the following groups of pain treatment:

  • Non-narcotics
  • Narcotics
  • Anti-arthritic treatments
  • Anti-migraine treatments.

This report delivers:

  • Key analysis split by region and class
  • Future market analysis right through to 2023
  • Analysis of key brands, generics, strategies in-place today and future strategies over the next 15 years
  • Analysis of key players in the pain market, current and future licensing strategies

This report examines the global pain drug market critically through a comprehensive review of available information. Sources used include internal databases, industrial databases, commercial news, company reports, published reports and economic research. Visiongain applies in-house financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The Global Pain Market, 2008-2023 concentrates on the following essential aspects of the market:

  • Forecast for the worldwide pain pharmaceutical market from 2008 to 2023
  • Forecasts for the principal submarkets from 2008 to 2023
  • Commercial prospects for the market-leading drugs, with sales forecasts from 2008 to 2023
  • Drivers and restraints in the pain market
  • Opportunities and threats in the pain market
  • Future therapies that will drive growth in this market
  • Pipeline developments with significant commercial potential
  • Currently marketed drugs with blockbuster potential
  • Discussion of unmet therapeutic needs and relative advantages of products.

Why you should buy this report:

  • To receive a comprehensive analysis of the prospects for pain drugs from 2008 to 2023
  • To discover predicted revenues, growth rates and other key metrics for leading pain treatments from 2008 to 2023
  • To discover "hot" pipeline developments and up-and-coming products
  • To determine the forces that influence the market for pain drugs:
  • Competitive characteristics of the market
  • Drivers
  • Restraints
  • Strengths, weaknesses, opportunities and threats in that market
  • To find out where the market is heading - both technologically and commercially - from 2008 onwards.

Contents

  • 1 Executive Summary
    • 1.1 The Pharmaceutical Pain Market Review: Entering a Crucial Period
    • 1.2 Aims, Scope and Format of the Report
  • 2 Introduction to Pain
    • 2.1 What is Pain?
      • 2.1.1 Historical aspects of Pain
    • 2.2 Pain Pathways
      • 2.2.1 WHO Pain Ladder
    • 2.3 Classification and Types of Pain
      • 2.3.1 Acute Pain
      • 2.3.2 Chronic Pain
        • 2.3.2.1 Psychosocial Effects of Chronic Pain
        • 2.3.2.2 The Financial Burden of Chronic Pain
        • 2.3.2.3 Chronic Cancer Pain
        • 2.3.2.4 Breakthrough Cancer Pain
    • 2.4 Neuropathic Pain
      • 2.4.1 Distinguishing Neuropathic Pain
    • 2.5 Neurochemistry of Pain
      • 2.5.1 Prostaglandins
      • 2.5.2 Opioids
    • 2.6 Pain Treatments
    • 2.7 OTC Pain Relievers
  • 3 An Overview of the Global Pain Pharmaceutical Market 2008-2023
    • 3.1 The Global Pain Pharmaceutical Market Analysis
      • 3.1.1 Celebrex Currently Leads the Pain Pharma Market
      • 3.1.2 The Non-Narcotics Segment Currently Dominates the Pain Market - But Will This Last?
    • 3.2 Major Success in the Pain Pharmaceutical Market Has Proved to Be Elusive to Date
    • 3.3 While the Past Has Been Difficult for Pain Management, There is Optimism for the Future
  • 4 The Global Non-Narcotics Market 2008-2023
    • 4.1 Non-Narcotics Market Analysis
    • 4.2 Efferalgan Currently Leads the Non-Narcotics Market - But Will This Last?
      • 4.2.1 Development of Efferalgan (Paracetamol)
    • 4.3 Tylenol Set to Reach Blockbuster Status
      • 4.3.1 Development of Tylenol (Paracetamol)
    • 4.4 Aspirin Bayer - Huge Amount of Line Extensions Keeping Sales Up
      • 4.4.1 Aspirin Bayer (Acetylsalicylic Acid)
    • 4.5 Advil Set to Exhibit Strong Growth?
      • 4.5.1 Advil (Ibuprofen)
    • 4.6 Tramal - How Will Sales Develop?
      • 4.6.1 Development of Tramal (Tramadol)
    • 4.7 The Non-Narcotics Market Currently Dominates the Pain Industry
  • 5 The Global Narcotics Market 2008-2023
    • 5.1 Narcotics Market Analysis
    • 5.2 Oxycontin - Beset by Major Challenges
      • 5.2.1 Development of Oxycontin (Oxycodone)
    • 5.3 Duragesic
      • 5.3.1 Development of Duragesic (Fentanyl)
    • 5.4 Oxycodone TEVA
      • 5.4.1 Oxycodone
    • 5.5 Fentanyl MYLA - How Will Sales Develop?
      • 5.5.1 Fentanyl
    • 5.6 Fentanyl NOVT - How Will Sales Develop?
    • 5.7 Total Sales in the Narcotics Market Will Increase Despite Being Crowded
  • 6 The Global Anti-Arthritic Market 2008-2023
    • 6.1 Anti-Arthritic Market Analysis
    • 6.2 Pfizer's Celebrex Dominates the Market, But Will This Last?
      • 6.2.1 Development of Celebrex (Celecoxib)
    • 6.3 Voltaren - How Will Sales Develop?
      • 6.3.1 Development of Voltaren (Diclofenac)
    • 6.4 Arcoxia Has Reduced Gastro Intestinal Effects
      • 6.4.1 Development of Arcoxia (Etoricoxib)
    • 6.5 Mobic Will Suffer from Generic Competition
      • 6.5.1 Development of Mobic (Meloxicam)
    • 6.6 Arthrotec Will Decline in Growth
      • 6.6.1 Development of Arthrotec (Diclofenac/Misoprostol)
    • 6.7 Rises Predicted for Global Arthritis Market
  • 7 The Global Anti-Migraine Market 2008-2023
    • 7.1 Anti-Migraine Market Analysis
    • 7.2 GSK's Blockbuster Imitrex/Imigran - How Will Sales Develop?
      • 7.2.1 Development of Imitrex/Imigran (Sumatriptan)
    • 7.3 Merck & Co's Maxalt - The New Market Leader Perhaps?
      • 7.3.1 Development of Maxalt (Rizatriptan)
    • 7.4 Zomig Shows Positive Growth
      • 7.4.1 Development of Zomig (Zolmitriptan)
    • 7.5 Relpax - How Will Sales Develop?
      • 7.5.1 Development of Relpax (Eletriptan)
    • 7.6 Naramig - How Will Sales Develop?
      • 7.6.1 Development of Naramig (Naratriptan)
    • 7.7 What Does the Future Hold for Migraine Therapy?
    • 7.8 What are the Unmet Needs in the Management of Migraine
  • 8 SWOT Analysis
    • 8.1 SWOT Analysis of the Global Pain Market
    • 8.2 Market Drivers
    • 8.3 Market Restraints
    • 8.4 The Pain Market Suffered After the Withdrawal of COX-2 Inhibitors
    • 8.5 Lack of Adequate Reimbursement Limits Potential of Pain Drugs
    • 8.6 Patients Dependent on Reformulations of Existing Drugs
    • 8.7 The Narcotics Market Suffers from Serious Side Effects
    • 8.8 The Under-Treatment of Pain
    • 8.9 How Might These Findings Affect the Market for Pain Drugs?
    • 8.10 The Future of the Pain Market - Closing Comments
      • 8.10.1 Shortcomings in the Attitude Towards Pain Management Illustrate the Need for the Proper Use of New and Existing Pain Management Therapies
      • 8.10.2 Analgesic Effect of Established Drugs for Other Diseases Will Continue to be of Relevance to the Pain Management Market
      • 8.10.3 Personalised Pain Management Therapy
  • 9 Pipeline Products for the Treatment of Pain
    • 9.1 The Pipeline in the Pain Market is Large and Expanding
    • 9.2 The Potential of the Pain Market Has Encouraged R&D Efforts
    • 9.3 Innovation Rules for Early-Stage Pipeline Drugs
    • 9.4 Late-Stage Pipeline Products in the Non-Narcotics Market
    • 9.5 Late-Stage Pipeline Products in the Narcotics Market
    • 9.6 Late-Stage Pipeline Products in the Anti-Arthritic Market
    • 9.7 Late-Stage Pipeline Products in the Anti-Migraine Market
    • 9.8 The Pain Pipeline Shows Short- and Long-Term Potential
  • 10 Future Therapies
    • 10.1 Cannabinoids and Pain: An Alternative to Opioids?
    • 10.2 Experimentally Induced Acute Pain
    • 10.3 Post Surgical Acute Pain
    • 10.4 Chronic Pain
    • 10.5 Sativex
      • 10.5.1 European Phase III Trials of Sativex
      • 10.5.2 Sativex Approved for Cancer Pain
    • 10.6 Cannabinoids and Pain: a Lucrative Market?
    • 10.7 The Future of Pain Research
    • 10.8 Advanced Drug Delivery
      • 10.8.1 Delivery of Poorly-Soluble Drugs
      • 10.8.2 Examples of Poorly-Water-Soluble Drugs
  • 11 Conclusions
    • 11.1 The Pain Market is Heading for Consistent Financial Growth
    • 11.2 Will the Non-Narcotics Segment Dominate the Pain Market in Future?
    • 11.3 The Narcotics Market Will be Hampered by Controversial Issues
    • 11.4 The Anti-Arthritic Market Shows No Signs of Slowing Down
    • 11.5 The Anti-Migraine Market Will Suffer Due to Patent Expiry of Key Products
    • 11.6 Major Success in the Pain Pharmaceutical Market Has Proved to Be Elusive to Date
    • 11.7 Why Growth in the Pain Market Will Continue
  • List of Tables
    • Table 3.1 The Global Pain Pharmaceutical Market Forecast ($m), 2008-2023
    • Table 3.2 Revenues ($m), 6-Year CAGR (%) and Market Share (%) for the Leading Pain Markets, 2007 & 2013
    • Table 3.3 Top Ten Products in the Pain Market ($m), 2007
    • Table 4.1 The World Non-Narcotics Market ($m) Forecast 2008-2023
    • Table 5.1 The World Narcotics Market ($m) Forecast 2008-2023
    • Table 6.1 The World Anti-Arthritic Market ($m) Forecast 2008-2023
    • Table 7.1 The World Anti-Migraine Market ($m) Forecast 2008-2023
    • Table 8.1 A SWOT Chart for the Pain Market, 2008-2013
    • Table 9.1 Late-Stage Non-Narcotic Pipeline Drugs for Pain, 2008
    • Table 9.2 Late-Stage Narcotic Pipeline Drugs for Pain, 2008
    • Table 9.3 Late-Stage Anti-Arthritic Pipeline Drugs for Pain, 2008
    • Table 9.4 Late-Stage Anti-Migraine Pipeline Drugs for Pain, 2008
  • List of Figures
    • Figure 3.1 The Global Pain Pharmaceutical Market Revenue Forecast ($m), 2008-2023
    • Figure 3.2 Leading Pain Markets' Revenue ($m) Comparison, 2007 & 2013
    • Figure 3.3 Leading Pain Sectors' Market Share (%), 2007
    • Figure 3.4 Leading Pain Sectors' Market Share (%), 2013
    • Figure 4.1 Non-Narcotics World Market Revenue Forecast ($m), 2008-2023
    • Figure 4.2 Efferalgan Revenue Forecast ($m), 2008-2023
    • Figure 4.3 Tylenol Revenue Forecast ($m), 2008-2023
    • Figure 4.4 Aspirin Bayer Revenue Forecast ($m), 2008-2023
    • Figure 4.5 Advil Revenue Forecast ($m), 2008-2023
    • Figure 4.6 Tramal Revenue Forecast ($m), 2008-2023
    • Figure 5.1 Narcotics World Market Revenue Forecast ($m), 2008-2023
    • Figure 5.2 Oxycontin Revenue Forecast ($m), 2008-2023
    • Figure 5.3 Duragesic Revenue Forecast ($m), 2008-2023
    • Figure 5.4 Oxycodone TEVA Revenue Forecast ($m), 2008-2023
    • Figure 5.5 Fentanyl MYLA Revenue Forecast ($m), 2008-2023
    • Figure 5.6 Fentanyl NOVT Revenue Forecast ($m), 2008-2023
    • Figure 6.1 Anti-Arthritic World Market Revenue Forecast ($m), 2008-2023
    • Figure 6.2 Celebrex Revenue Forecast ($m), 2008-2023
    • Figure 6.3 Voltaren Revenue Forecast ($m), 2008-2023
    • Figure 6.4 Arcoxia Revenue Forecast ($m), 2008-2023
    • Figure 6.5 Mobic Revenue Forecast ($m), 2008-2023
    • Figure 6.6 Arthrotec Revenue Forecast ($m), 2008-2023
    • Figure 7.1 Anti-Migraine World Market Revenue Forecast ($m), 2008-2023
    • Figure 7.2 Imitrex/Imigran Revenue Forecast ($m), 2008-2023
    • Figure 7.3 Maxalt Revenue Forecast ($m), 2008-2023
    • Figure 7.4 Zomig Revenue Forecast ($m), 2008-2023
    • Figure 7.5 Relpax Revenue Forecast ($m), 2008-2023
    • Figure 7.6 Naramig Revenue Forecast ($m), 2008-2023
    • Figure 11.1 The Global Pain Pharmaceutical Market Revenue Forecast ($m), 2008-2023
  • Companies listed:
    • AstraZeneca
    • Abbott
    • Acura
    • Alpharma
    • Anesiva
    • Astellas
    • Bayer
    • Biovail
    • Bristol Myers Squibb
    • Daiichi Sankyo
    • Dr. Reddy's Laboratories
    • Eisai
    • Ethypharm
    • Gruenenthal
    • GSK
    • GW pharmaceuticals
    • Horizon
    • Idea
    • Javelin
    • Johns Hopkins University
    • Johnson & Johnson
    • Kowa
    • Labopharm
    • MAP Pharmaceuticals
    • Meda
    • Merck & Co
    • NicOx
    • Novartis
    • Ono
    • Pacira Pharmaceuticals
    • Pain Therapeutics
    • Paion
    • Pfizer
    • PLx Pharma
    • Pozen
    • Purdue Pharma
    • QRxPharma
    • Ranbaxy
    • Recordati
    • Roxro
    • Shionogi
    • Symbollon
    • Teva
    • UCB
    • Wex
    • Winston Laboratories
    • Zogenix